STE Quote, Financials, Valuation and Earnings

Jazz Pharmaceuticals Plc has a net margin of 13.18% compared to STERIS Plc (Ireland)'s net margin of 22.33%. STERIS Plc (Ireland)'s return on equity of 10.26% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.

STERIS Plc (Ireland) has a consensus price target of $281.63, signalling upside risk potential of 8.57%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $208.50 which suggests that it could grow by 24.92%. Given that Jazz Pharmaceuticals Plc has higher upside potential than STERIS Plc (Ireland), analysts believe Jazz Pharmaceuticals Plc is more attractive than STERIS Plc (Ireland).

STERIS Plc (Ireland) has a beta of 1.011, which suggesting that the stock is 1.146% more volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.305, suggesting its less volatile than the S&P 500 by 69.522%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 0.93%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend. STERIS Plc (Ireland)'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are larger than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. STERIS Plc (Ireland)'s net income of $192.5M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 36.92x while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.50x versus 2.45x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband, Inc. has a net margin of 13.18% compared to STERIS Plc (Ireland)'s net margin of -321.33%. STERIS Plc (Ireland)'s return on equity of 10.26% beat Nutriband, Inc.'s return on equity of -117.44%.

STERIS Plc (Ireland) has a consensus price target of $281.63, signalling upside risk potential of 8.57%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 196.44%. Given that Nutriband, Inc. has higher upside potential than STERIS Plc (Ireland), analysts believe Nutriband, Inc. is more attractive than STERIS Plc (Ireland).

STERIS Plc (Ireland) has a beta of 1.011, which suggesting that the stock is 1.146% more volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.907, suggesting its more volatile than the S&P 500 by 90.735%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 0.93%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend. STERIS Plc (Ireland)'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are larger than Nutriband, Inc. quarterly revenues of $622.5K. STERIS Plc (Ireland)'s net income of $192.5M is higher than Nutriband, Inc.'s net income of -$2M. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 36.92x while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.50x versus 21.85x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Prothena Corp. Plc has a net margin of 13.18% compared to STERIS Plc (Ireland)'s net margin of -1513.09%. STERIS Plc (Ireland)'s return on equity of 10.26% beat Prothena Corp. Plc's return on equity of -67.47%.

STERIS Plc (Ireland) has a consensus price target of $281.63, signalling upside risk potential of 8.57%. On the other hand Prothena Corp. Plc has an analysts' consensus of $20.33 which suggests that it could grow by 82.2%. Given that Prothena Corp. Plc has higher upside potential than STERIS Plc (Ireland), analysts believe Prothena Corp. Plc is more attractive than STERIS Plc (Ireland).

STERIS Plc (Ireland) has a beta of 1.011, which suggesting that the stock is 1.146% more volatile than S&P 500. In comparison Prothena Corp. Plc has a beta of -0.099, suggesting its less volatile than the S&P 500 by 109.869%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 0.93%. Prothena Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Prothena Corp. Plc pays out -- of its earnings as a dividend. STERIS Plc (Ireland)'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are larger than Prothena Corp. Plc quarterly revenues of $2.4M. STERIS Plc (Ireland)'s net income of $192.5M is higher than Prothena Corp. Plc's net income of -$36.5M. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 36.92x while Prothena Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.50x versus 50.97x for Prothena Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of 13.18% compared to STERIS Plc (Ireland)'s net margin of 11.55%. STERIS Plc (Ireland)'s return on equity of 10.26% beat Zimmer Biomet Holdings, Inc.'s return on equity of 6.45%.

STERIS Plc (Ireland) has a consensus price target of $281.63, signalling upside risk potential of 8.57%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.92 which suggests that it could grow by 10.54%. Given that Zimmer Biomet Holdings, Inc. has higher upside potential than STERIS Plc (Ireland), analysts believe Zimmer Biomet Holdings, Inc. is more attractive than STERIS Plc (Ireland).

STERIS Plc (Ireland) has a beta of 1.011, which suggesting that the stock is 1.146% more volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.541%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 0.93%. Zimmer Biomet Holdings, Inc. offers a yield of 1.03% to investors and pays a quarterly dividend of $0.24 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 21.66% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are smaller than Zimmer Biomet Holdings, Inc. quarterly revenues of $2B. STERIS Plc (Ireland)'s net income of $192.5M is lower than Zimmer Biomet Holdings, Inc.'s net income of $231.2M. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 36.92x while Zimmer Biomet Holdings, Inc.'s PE ratio is 23.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.50x versus 2.31x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.